
Conference Coverage
about 2 months ago
ARVO 2026: Retinal neuroprotective role of Cav1about 2 months ago
ARVO 2026: 3D imaging and deep learning for retinal diseaseabout 2 months ago
ARVO 2026: Global RETFound studyabout 2 months ago
ARVO 2026: Corneal nerve metrics with CellChek Cabout 2 months ago
ARVO 2026: Optogenetic REMAIN 3 year study dataLatest News

FDA grants priority review to Satralizumab sBLA for thyroid eye disease

From detection to decision-making: Navigating disease progression and treatment in geographic atrophy

4DMT completes enrollment in 4FRONT-2, global phase 3 trial of 4D-150 in wet AMD

Detecting peripheral retinal lesions in children with myopia

FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages

Shorts










Ophthalmology Times Digital Edition






Podcasts
Continuing Medical Education
All News

In a preference study, Csaky and colleagues found that lesion growth rate reduction was the primary driver of GA treatment decisions among US retina specialists, with greater risk tolerance for foveal-threatening lesions.

Study finds ChatGPT-5 overpredicts success after macular hole surgery—beating specialists on paper but missing failures.

Diana Canto-Sims, OD, owner of Buena Vista Optical, discusses how Meta's donation of free AI glasses to blind veterans could close longstanding access gaps in low vision care—and where voice-command wearables fit alongside traditional rehabilitation tools.

A large real-world cohort study finds OSA is associated with elevated glaucoma risk, though whether positive airway pressure therapy itself plays a role remains unclear.

Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.

Their conversation covers a holistic, cross-specialty approach to ocular surface disease and the unmet need driving a new model of dry eye care in Ireland.

ARPA-H funds OCULAB to build tear-duct sensors that track biomarkers in real time and microdose drugs, transforming dry-eye and systemic care.

The newly formed biotech will use the financing to push MMT-205, a bispecific antibody that directly activates Tie2 while inhibiting VEGF, toward IND-enabling studies, with first-in-human trials slated for 2027.

Atsena reported that, since enrollment opened in May 2026, it has already accrued approximately 10% of the pivotal cohort and expects the pace to accelerate as additional sites across North America and Europe are activated.

NCX 470 glaucoma drop gains China regulatory encouragement, clearing path for near-term filings and expanding commercial upside beyond the US.

A retrospective study finds that direct selective laser trabeculoplasty significantly lowers intraocular pressure, with the greatest benefit seen in treatment-naive eyes.

A prospective pilot series finds Keraring implantation cuts refractive cylinder by 61% in non-ectatic corneas, opening a new conversation about ICRS indications.

The 2-day program at the Gaylord Opryland Resort will bring together established and emerging eye care leaders for sessions on leadership development, artificial intelligence, inclusion, and career growth.

Douglas D. Koch, MD, and Karolinne Maia Rocha, MD, PhD, discuss the optics behind enhanced monofocal lenses, patient selection, and how to set expectations.

A balanced mix of AI-generated and smartphone-captured images eliminated the domain-specific failures seen with single-source training






























